Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
Status:
Completed
Trial end date:
2019-07-08
Target enrollment:
Participant gender:
Summary
An unmet medical need exists for patients with moderate and severe asthma who continue to
demonstrate symptoms despite being on standard of care medications, and are not eligible for
other biologic therapies developed or in development for T2-high(allergic/eosinophilic)
asthma. The purpose of this study was to determine if CJM112, an anti-IL-17A antibody,
displayed the clinical efficacy and safety profile to support further development in patients
with inadequately controlled moderate to severe asthma with low IgE and low circulating
eosinophil levels.